ANI Pharmaceuticals Reports First Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
ANI Pharma (ANIP) Tops Q1 EPS by 33c, Revenues Beat
May 7, 2021 6:52 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.04, $0.33 better than the analyst estimate of $0.71. Revenue for the quarter came in at $54.5 million versus the consensus estimate of $46.8 million.
First Quarter 2021 Financial Highlights:
Net revenues were $54.5 million compared to $49.8 million in Q1 2020.GAAP net income was $0.1 million, and diluted GAAP earnings per share was $0.01.Adjusted non-GAAP EBITDA was $18.9 million.Adjusted non-GAAP diluted earnings per share was $1.04.Cash and cash equivalents were $25.1 million, net accounts receivable was $91.9 million,... More



